Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2024 results mace Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2024 results mace Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2024 results mace Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2024 results mace Unveiling Cardiovascular Benefits of Oral Semaglutide in High-Risk Type 2 Diabetes: Findings from the SOUL Trial in your area.
The SOUL trial (Semaglutide Cardiovascular Outcomes Trial) was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial that enrolled 9,650 patients aged 50 years or older with
23.90
In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8
28.94
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study | Diabetes Therapy
25.39
Trial Scorecard: SOUL
20.51
Cardiovascular Outcomes Associated with Semaglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis
28.94
Canadian Perspectives 2025 Whiteboard on the SOUL Trial
29.22
An oral formulation of semaglutide lowered the risk major adverse cardiovascular events by 14% in four years, with no change in safety profile compared to placebo, according to the SOUL study. #ACC25
26.85
